SFX by Ex Libris Inc.

Title:	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
Source:	Journal of Medicinal Chemistry [0022-2623] Theodoulou, Natalie yr:2015

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Xue, X. "Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation." Journal of medicinal chemistry 59.4 (2016): 1565-1579.
description	2.	Martin, Laetitia J. "Structure-based design of an in vivo active selective BRD9 inhibitor." Journal of medicinal chemistry 59.10 (2016): 4462-4475.
description	3.	Stoeckmann, H. "Glycan-mediated ligand-controlled click chemistry for small molecule target identification." ChemBioChem 17.2 (2015): 150-154.
description	4.	Hewitt, Michael C. "Development of methyl isoxazoleazepines as inhibitors of BET." Bioorganic and medicinal chemistry letters 25.9 (2015): 1842-8.
description	5.	Clark, Peter G K G. "LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor." Angewandte Chemie (International ed.) 54.21 (2015): 6217-21.
description	6.	Battula, S. R. K. R. "Stereoselective synthesis of 4-aminobenzo[c][1,2]thiazine via modification of the Harmata benzothiazine synthesis." RSC Advances 6.61 (2016): 55710-55714.
description	7.	Shu, Shaokun i. "Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer." Nature 529.7586 (2016): 413-417.
description	8.	Tao, Z. "Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors." Journal of medicinal chemistry 50.7 (2007): 1514-4.
description	9.	Fedorov, O. "[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of diverse bromodomains." Journal of medicinal chemistry 57.2 (2014): 462-476.
description	10.	"A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36.15.
description	11.	Albrecht, Brian K. "Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinaseâ ." Journal of medicinal chemistry 51.10 (2008): 2879-2882.
description	12.	Karim, Rezaul M. "An Advanced Tool To Interrogate BRD9." Journal of medicinal chemistry 59.10 (2016): 4459-4461.
description	13.	Jung, M. "Targeting BET bromodomains for cancer treatment." Epigenomics 7.3 (2015): 487-501.
description	14.	Picaud, S. "9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain." Journal of medicinal chemistry 58.6 (2015): 2718-2736.
description	15.	Healy, Alan R. "Stereochemical Assignment of the Protein-Protein Interaction Inhibitor JBIR-22 by Total Synthesis." Angewandte Chemie (International ed.) 54.13 (2015): 4046-4050.
description	16.	Harner, Mary J. "Fragment-Based Screening of the Bromodomain of ATAD2." Journal of medicinal chemistry 57.22 (2014): 4294967295-9692.
description	17.	Galbraith, Matthew D. "HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia." Cell 153.6 (2013): 1327-1339.
description	18.	Im, G. "Indolyne Experimental and Computational Studies: Synthetic Applications and Origins of Selectivities of Nucleophilic Additions." Journal of the American Chemical Society 132.50 (2010): 17933-17944.
description	19.	Moosavi-Movahedi, A. "Design, synthesis, and biological evaluation of a cephalosporin-monohydroguaiaretic acid prodrug activated by a monoclonal antibody-beta-lactamase conjugate." Bioorganic & medicinal chemistry 10.9 (2002): 2927-2932.
description	20.	Gustafsson, D. "Oral direct thrombin inhibitors in clinical development." Journal of internal medicine 254.4 (2003): 322-334.